Business Wire

PROCURITAS

24.8.2021 09:32:05 CEST | Business Wire | Press release

Share
Procuritas Sells Dantherm Following the Group’s Successful Transformational Growth

Procuritas Capital Investors V (“Procuritas”), the private equity investor focused on investing in and growing Nordic mid-market companies, today announced that it has sold Dantherm Group (“Dantherm”), the leading provider of climate control products and solutions, to German private equity fund, DBAG Fund VIII, advised by Deutsche Beteiligungs AG.

Headquartered in Denmark, Dantherm has more than 60 years’ experience in designing and manufacturing high quality and energy efficient equipment for heating, cooling, drying, cleaning and ventilation for a wide range of portable and installed applications.

After acquiring the business in 2016, Procuritas invested in Dantherm to enable it to expand the geographical presence, to expand the product range and to take a leading market position in its core businesses in Europe.

Alongside the expansion of the business’ sales capabilities, strengthened senior management team and investment in its own manufacturing capacity, Procuritas utilized its extensive value creation expertise and network to partner with the Group to implement an active buy and build strategy. Under Procuritas’ ownership, Dantherm acquired close to 20 entities in its core markets of the UK, Italy, Denmark, Germany, France, Poland, Russia, Switzerland and Spain, realizing considerable integration synergies and significantly expanding the group’s capabilities and scale, resulting in a more than threefold rise in revenues and EBITDA growth of almost 700%.

Dantherm now operates in Norway, Sweden, Denmark, United Kingdom, Germany, Switzerland, Italy, Spain, Poland, Russia, France and China, where its strong brands – Aerial, Aircenter, BioCool, Calorex, Dantherm, Heylo, Master, SET and Sovelor – have well-established market positions. The group’s customers benefit from a comprehensive knowledge base and the experience and expertise from more than three million climate control products and solutions sold worldwide.

Hans Wikse, Partner at Procuritas, commented: “We are delighted to have sold Dantherm to DBAG Fund VIII, advised by Deutsche Beteiligungs AG, having received keen interest from several parties. We think it is a great fit for the company and they will have a great future. Dantherm has been a classic buy and build investment for Procuritas and our strategy was implemented following the methodical process we have undertaken with many other investments over the years.”

Bjarke Brøns, CEO of Dantherm commented: “ Over the past six years we have transformed Dantherm to become a market leading provider of selected climate control solutions. Procuritas has been a great partner to work with and their expertise in transforming companies through acquisition and by institutionalizing the business has been a great support as we have grown the Group. We see continued and extended market opportunities within our business and are excited to continue the development of Dantherm in the future with DBAG.”

Oskar Lindholm-Wu, Partner at Procuritas, commented: “It has been a pleasure to work with the Dantherm team, putting our passion for building strong sustainable businesses through transformational growth to work. Together, we have achieved remarkable growth, transforming the group into the leader in all its core markets across Europe. We wish Dantherm a prosperous future.”

DC Advisory served as M&A advisor, Kromann Reumert as legal advisor and EY as financial due diligence advisor to Procuritas and Dantherm in connection with the transaction.

About Procuritas

Procuritas is a private equity investor, focused on investing in and growing Nordic mid-market companies. With a passion for business, hands-on active ownership approach and more than thirty-year record from a large variety of transactions, it has supported more than 45 companies in accelerating their growth and realizing their true business potential. As owners, Procuritas is characterized by its enthusiasm, commitment, and strong belief that it is an ally in the quest to build strong and sustainable businesses. Read more at www.procuritas.com .

About Dantherm Group

Headquartered in Skive, Denmark, the Dantherm Group is a European leader in portable and installed climate control solutions for a wide range of industries within heating, drying, cooling, cleaning and ventilation. Dantherm has subsidiaries in Norway, Sweden, UK, Germany, Switzerland, Italy, France, Spain, Poland, Russia and China. In 2016 the Dantherm Group was acquired by Procuritas Capital Investors V LP. Read more at www.danthermgroup.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye